Trial investigators are aiming to study the safety and resulting immune response, following participants up to six months post-vaccination. The trial involves 600 adults recruited from the company’s prior late-stage COVID-19 vaccine trial. Participants must receive both COVID-19 vaccines at least six months before joining the new study, Pfizer said in a statement. Participants were randomly assigned to one of the following groups:Pneumococcal vaccine and a third dose of Pfizer’s COVID-19 vaccinePneumococcal vaccine and a placeboThird dose of Pfizer’s COVID-19 vaccine and a placeboDO WE NEED COVID-19 BOOSTER VACCINES? While everyone needs pneumococcal vaccines, it’s especially important for babies, adults over 65 and people with weakened immune systems and underlying health conditions, HHS says.

Source: Fox News May 24, 2021 19:52 UTC